Participatory Research to Understand the Translation of HPV Vaccine Policy

了解 HPV 疫苗政策转化的参与式研究

• 批准号: 7497826
• 负责人: Andrew Louis Sussman
• 金额: $ 20.25万
• 依托单位: UNIVERSITY OF NEW MEXICO
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-09-22 至 2010-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7497826
• 关键词: 12 year old; Administrator; Advisory Committees; Affect; Anogenital venereal warts; Area; Behavioral Research; Case Study; Cervical; Child; Collaborations; Communities; Community Health; Country; Data; Data Collection; Decision Making; Development; District of Columbia; Education; Ensure; Ethnography; Face; Focus Groups; Funding; Gardasil; Goals; Government; Head; Health Personnel; Health Policy; Healthcare; Hispanics; Human Papilloma Virus Vaccine; Human Papillomavirus; Immunization; Incidence; Individual; Infection; Information Dissemination; Institution; Insurance; Interview; Lesion; Malignant Neoplasms; Malignant neoplasm of cervix uteri; Marketing; Mediation; Medical Societies; Mexico; Morbidity - disease rate; New Mexico; Nurses; Parenting Education; Parents; Patients; Perception; Play; Policies; Policy Maker; Premalignant; Primary Health Care; Primary Schools; Process; Provider; Public Health; Public Policy; Purpose; Qualitative Research; Range; Recommendation; Religious Belief; Reporting; Research; Resources; Role; Schools; Scientific Advances and Accomplishments; Scientist; Series; Societies; Sorting - Cell Movement; Statutes and Laws; Structure; System; Toes; Translations; United States Food and Drug Administration; Vaccination; Vaccines; Woman; Work; base; cancer health disparity; cultural values; disorder prevention; experience; girls; health disparity; methionylmethionine; mortality; programs; response; social; vaccine delivery

DESCRIPTION (provided by applicant): In June of 2006, the FDA approved Merck's vaccine "Guardasil" which protects against 4 types of HPV infections, two which cause abnormal cervical dysplagia and two which cause genital warts. In the 15 months since the approval and the subsequent recommendation by the Advisory Committee on Immunization Practice (ACIP) that the vaccine be routinely administered to 11-12 year old girls, legislators in 41 states and the District of Columbia have introduced legislation to require, fund, or educate the public about the HPV vaccine, and at least 17 states have enacted some sort of legislation, including the state of New Mexico. In this application we propose to study the process of implementing policy regarding the HPV vaccine in the state of New Mexico, and related programmatic efforts to offer the vaccine and relevant education to parents and the public. This study is responsive to the call for proposals to conduct research on three areas of action: public policy, health care, and disease prevention. The Specific Aims are as follows: 1. Using a participatory process, identify and convene a stakeholder group composed of individuals involved in the health policy context 2. Explore the translation and impact of health policy initiatives regarding the dissemination of HPV vaccine and the promotion of informed decision making in New Mexico public schools and primary care settings. a. Conduct semi structured interviews with health policy makers, primary care providers, school based health providers and school administrators, in order to determine their perceptions of the roles b. Conduct focus group discussions with parents of 5th grade children c. Conduct ethnographic observations of the ongoing debate about the HPV vaccine dissemination policy 3. Together with the stakeholder group, interpret the data, develop and disseminate health policy recommendations regarding initiatives to support HPV vaccine dissemination and informed decision making leading to the reduction of cervical cancer health disparities in New Mexico. PUBLIC HEALTH RELEVANCE: The recent approval of the HPV vaccine is an important scientific advance but faces challenges in dissemination and implementation. This study will help to develop a better understanding of the factors that contribute to the development of HPV vaccine policy. These findings will be used to work toward the creation of strategies, both at the primary care and health policy level, to promote informed decision among patients with regard to the HPV vaccine that are consistent with community values.

描述（申请人提供）：2006年6月，FDA批准了默克公司的疫苗“Guardasil”，该疫苗可预防4种类型的HPV感染，其中两种会导致异常宫颈发育不良，另两种会导致尖锐湿疣。自免疫实践咨询委员会 (ACIP) 批准并随后建议对 11-12 岁女孩常规接种疫苗以来的 15 个月内，41 个州和哥伦比亚特区的立法者已立法要求：基金或对公众进行有关 HPV 疫苗的教育，至少 17 个州已经颁布了某种立法，其中包括新墨西哥州。在本申请中，我们建议研究新墨西哥州 HPV 疫苗政策的实施过程，以及向家长和公众提供疫苗和相关教育的相关计划工作。这项研究响应了对公共政策、医疗保健和疾病预防这三个行动领域进行研究的提案的号召。具体目标如下： 1. 采用参与式流程，确定并召集一个由参与卫生政策背景的个人组成的利益相关者小组 2. 探索有关传播 HPV 疫苗和促进新墨西哥州公立学校和初级保健机构的知情决策。一个。与卫生政策制定者、初级保健提供者、学校卫生提供者和学校管理人员进行半结构化访谈，以确定他们对角色的看法 b．与五年级儿童的家长进行焦点小组讨论 c.对正在进行的有关 HPV 疫苗传播政策的争论进行人种学观察 3. 与利益相关者团体一起，解释数据、制定和传播有关支持 HPV 疫苗传播和知情决策的举措的卫生政策建议，从而导致宫颈癌健康状况下降新墨西哥州的不平等。公共卫生相关性：最近批准的 HPV 疫苗是一项重要的科学进步，但在传播和实施方面面临挑战。这项研究将有助于更好地了解有助于制定 HPV 疫苗政策的因素。这些研究结果将用于在初级保健和卫生政策层面制定策略，以促进患者就 HPV 疫苗做出符合社区价值观的知情决策。